Kiniksa Pharmaceuticals International, plc (KNSA)
KNSA Stock Price Chart
Explore Kiniksa Pharmaceuticals International, plc interactive price chart. Choose custom timeframes to analyze KNSA price movements and trends.
KNSA Company Profile
Discover essential business fundamentals and corporate details for Kiniksa Pharmaceuticals International, plc (KNSA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
24 May 2018
Employees
366.00
Website
https://www.kiniksa.comCEO
Sanj K. Patel
Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA Financial Timeline
Browse a chronological timeline of Kiniksa Pharmaceuticals International, plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is $0.30, while revenue estimate is $226.49m.
Earnings released on 28 Apr 2026
EPS came in at $0.27 surpassing the estimated $0.18 by +50.00%, while revenue for the quarter reached $214.27m , beating expectations by +3.96%.
Earnings released on 24 Feb 2026
EPS came in at $0.17 falling short of the estimated $0.29 by -41.38%, while revenue for the quarter reached $202.13m , beating expectations by +0.66%.
Earnings released on 28 Oct 2025
EPS came in at $0.23 falling short of the estimated $0.33 by -30.30%, while revenue for the quarter reached $180.86m , missing expectations by -8.24%.
Earnings released on 29 Jul 2025
EPS came in at $0.23 surpassing the estimated $0.18 by +27.78%, while revenue for the quarter reached $156.80m , missing expectations by -5.82%.
Earnings released on 29 Apr 2025
EPS came in at $0.11 surpassing the estimated $0.02 by +450.00%, while revenue for the quarter reached $137.79m , beating expectations by +4.48%.
Earnings released on 25 Feb 2025
EPS came in at -$0.12 falling short of the estimated -$0.06 by -100.00%, while revenue for the quarter reached $122.54m , missing expectations by -0.71%.
Earnings released on 29 Oct 2024
EPS came in at -$0.18 falling short of the estimated -$0.02 by -662.39%, while revenue for the quarter reached $112.21m , missing expectations by -9.05%.
Earnings released on 23 Jul 2024
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $108.63m , missing expectations by -1.51%.
Earnings released on 23 Apr 2024
EPS came in at -$0.25 falling short of the estimated -$0.14 by -78.57%, while revenue for the quarter reached $79.86m , beating expectations by +1.78%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 surpassing the estimated -$0.11 by +136.36%, while revenue for the quarter reached $83.40m , beating expectations by +15.79%.
Earnings released on 31 Oct 2023
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $67.05m , beating expectations by +4.03%.
Earnings released on 25 Jul 2023
EPS came in at -$0.02 surpassing the estimated -$0.16 by +87.50%, while revenue for the quarter reached $71.47m , beating expectations by +14.91%.
Earnings released on 2 May 2023
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $48.35m , beating expectations by +3.79%.
Earnings released on 28 Feb 2023
EPS came in at $0.06 surpassing the estimated -$0.23 by +126.09%, while revenue for the quarter reached $61.88m , beating expectations by +37.17%.
Earnings released on 1 Nov 2022
EPS came in at $0.67 surpassing the estimated $0.38 by +76.32%, while revenue for the quarter reached $99.14m , beating expectations by +5.94%.
Earnings released on 3 Aug 2022
EPS came in at -$0.29 surpassing the estimated -$0.43 by +32.56%, while revenue for the quarter reached $26.97m , missing expectations by -5.10%.
Earnings released on 3 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $32.19m , beating expectations by +6.93%.
Earnings released on 22 Feb 2022
EPS came in at -$0.53 falling short of the estimated -$0.44 by -20.45%, while revenue for the quarter reached $18.75m , beating expectations by +6.51%.
Earnings released on 1 Nov 2021
EPS came in at -$0.44 surpassing the estimated -$0.63 by +30.16%, while revenue for the quarter reached $12.10m , beating expectations by +37.76%.
Earnings released on 3 Aug 2021
EPS came in at -$0.61 surpassing the estimated -$0.69 by +11.59%, while revenue for the quarter reached $7.70m , meeting expectations.
KNSA Stock Performance
Access detailed KNSA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
